Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin
Abstract Background Anticoagulant therapies are used to prevent atrial fibrillation-related strokes, with warfarin and direct oral anticoagulant (DOAC) the most common. In this study, we incorporate direct health care costs, drug costs, travel costs, and lost working and leisure time costs to estima...
Guardado en:
Autores principales: | Mikko Pyykönen, Miika Linna, Markku Tykkyläinen, Eric Delmelle, Tiina Laatikainen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/29b7add63d014145ab3acdacf15ed968 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
por: Colombo GL, et al.
Publicado: (2021) -
Patient characteristics, adherence, and costs of oral anticoagulation therapy in non-valvular atrial fibrillation using the Dubai Real-World Claims Database
por: Moutaz El Kadri, et al.
Publicado: (2021) -
GIS-based accessibility analysis for network optimal location model
por: Sylvie Dubuc
Publicado: (2007) -
Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
por: Eue-Keun Choi, et al.
Publicado: (2021) -
Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Clara Bonanad, et al.
Publicado: (2021)